WO2000015218A1 - A new composition - Google Patents
A new composition Download PDFInfo
- Publication number
- WO2000015218A1 WO2000015218A1 PCT/SE1999/001597 SE9901597W WO0015218A1 WO 2000015218 A1 WO2000015218 A1 WO 2000015218A1 SE 9901597 W SE9901597 W SE 9901597W WO 0015218 A1 WO0015218 A1 WO 0015218A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- component
- pharmaceutical formulation
- disorders
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a composition which comprises a first component (a) which is ( ⁇ )-3-NN-dicyclobutylamino-8-fluoro-3,4-dihydro-2H- l-benzopyran-5- carboxamide hydrogen (2_?,3i.)-tartrate monohydrate and a second component (b) which is paroxetine, or a pharmaceutically acceptable salt and/or solvate thereof.
- the present invention also relates to a process for the preparation of the inventive composition, pharmaceutical formulations containing said composition and to the use of said composition either by concomitant administration or by separate administration as an improvement of the treatment of affective disorders such as depression, anxiety, obsessive compulsive disorder (OCD), etc.
- antidepressants take 2-4 weeks to reach full clinical effect. In contrast, the side effects occur immediately. Thus, slow onset of action of antidepressants leads to a vulnerable period for patients in which they experience the side effects, but rfot the therapeutic effects of drugs. There is often a heavy burden on the treating physician to persuade the patient to continue with the treatment during this period. Furthermore, in suicidal patients, as the onset of action is gradual, initiative may be regained without the experiencing of full reversal of symptoms, leaving a window of risk for suicide and a frequent requirement for hospitalization.
- the present invention is directed to a new composition
- a new composition comprising of a first component (a) which is the specific 5-HT ⁇ antagonist ( ⁇ -3-NN-d_cyclobutylamino-8-fluoro-3,4- dihydro-2H-l-benzopyran-5-carboxamide hydrogen (2_?,3i?)-tartrate monohydrate and a second component (b) which is paroxetine, in the form of the free base, or a pharmaceutically acceptable salt and/or solvate thereof.
- Said composition attains a faster onset of action and consequently, provides a more efficacious treatment of the patients . suffering form affective disorders, particularly depression.
- Paroxetine is a 5-HT reuptake inhibitor (SSRI) which is commercially available.
- Pharmaceutically acceptable salts of paroxetine such as the hydrochloride, hydrobromide, maleate, tartrate, acetate etc. are also included in the inventive composition. Also solvate forms such as the hydrate and hemihydrate of the salts are included.
- composition according to the present invention may exist in one pharmaceutical formulation comprising the component (a) and component (b), or in two different pharmaceutical formulations, one for component (a) and one for component (b).
- the pharmaceutical formulation may be in the form of tablets or capsules, powders, mixtures, solutions or other suitable pharmaceutical formulation forms such as patches and nasal formulations.
- composition of the present invention can be prepared such that component (a) is incorporated into the same pharmaceutical formulation as component (b) by e.g. mixing in a conventional way.
- the present invention also includes a method of improving the onset of therapeutic action by concomitant administration of a composition comprising of (R)-3-N,N- dicyclobutylamino-8-fluoro-3,4-dihydro-2H- 1 -benzopyran-5-carboxamide hydrogen (2 ⁇ ,3_?)-tartrate monohydrate and paroxetine.
- a further embodiment of the present invention is a kit containing a dosage unit of (R)-3- NN-dicyclobutylamino-8-fluoro-3,4-dihydro-2H- 1 -benzopyran-5-carboxamide hydrogen (2_?,3i?)-tartrate monohydrate and a dosage unit of a paroxetine, optionally with instructions for use.
- the compounds in the composition will normally be administered orally, rectally, transdermally, nasally or by injection, in the form of pharmaceutical formulations comprising the active ingredients in a pharmaceutically acceptable dosage form .
- the dosage form may be a solid, semisolid or liquid formulation.
- the active substances will constitute between 0.1 and 99% by weight of the formulation, more specifically between 0.5 and 20% by weight for formulations intended for injection and between 0.2 and 50% by weight for formulations suitable for oral administration.
- the pharmaceutical formulation comprises the active ingredients, optionally in association with adjuvants, excipients e.g. diluents, and/or inert carriers.
- the selected compounds may be mixed with a solid excipient, e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, a binder such as gelatin or poly- vinylpyrrolidone, disintegrants e.g. sodium starch glycolate, cross-linked PVP and cross- caramellose sodium and a lubricant such as magnesium stearate, calcium stearate, polyethylene glycol, waxes, paraffin, and the like, and an antisticking agent such as talc or colloidal silicon dioxide, and then compressed into tablets.
- a solid excipient e.g. lactose, saccharose, sorbitol, mannitol, starches such as potato starch, corn starch or amylopectin, cellulose derivatives, a binder such as gelatin or poly- vinylpyrrolidone, disintegrants e.g. sodium starch
- the cores may be coated with a polymer known to the man skilled in the art e.g. HPMC, HC or other cellulose derivatives or PNP, wherein the polymer is dissolved in water or a readily volatile organic solvent or mixture of organic solvents.
- a polymer known to the man skilled in the art e.g. HPMC, HC or other cellulose derivatives or PNP, wherein the polymer is dissolved in water or a readily volatile organic solvent or mixture of organic solvents.
- the tablets can be coated with a concentrated sugar solution which may contain e.g. gum arabic, gelatin, talcum, titanium dioxide, and the like.
- Dyestuffs may be added to these coatings for instance in order to readily distinguish between tablets containing different active substances or different amounts of the active compounds.
- the active substances may be admixed with e.g. a vegetable oil or polyethylene glycol.
- Hard gelatin capsules may contain granules of the active substances using any of the above mentioned excipients for tablets e.g. lactose, saccharose, sorbitol, mannitol, starches (e.g. potato starch, corn starch or amylopectin), cellulose derivatives, plasticizers, polyetheneglycol, waxes, lipids or gelatin. Also liquids or semisolids of the drug can be filled into hard gelatin capsules.
- Dosage units for rectal application can be solutions or suspensions or can be prepared in the form of suppositories comprising the active substances in a mixture with a neutral fatty base, or gelatine rectal capsules comprising the active substances in admixture with vegetable oil or paraffin oil.
- Liquid formulations for oral application may be in the form of solutions, syrups or suspensions, for example " solutions containing from about 0.2% to about 20% by weight of the active substances herein described, the balance being sugar and mixture of ethanol, water, glycerol and propylene glycol.
- such liquid formulations may contain colouring agents, flavouring agents, saccharin and carboxymethyl-cellulose as a thickening agent or other excipients known to a person skilled in the art.
- Solutions for parenteral applications by injection can be prepared in an aqueous solution of a water-soluble pharmaceutically acceptable salt of the active substances, preferably in a concentration of from about 0.5% to about 10% by weight. These solutions may also contain stabilizing agents and/or buffering agents and may conveniently be provided in various dosage unit ampoules. Suitable daily doses of the active compounds in the composition of the invention in therapeutic treatment of humans are about 0.01-100 mg/kg bodyweight for peroral administration and 0.001-100 mg kg bodyweight for parenteral administration.
- the daily doses of the active ingredient C_ ⁇ -3-NN-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-l- benzopyran-5-carboxamide hydrogen (2i?,3i?)-tartrate monohydrate may very well differ from the daily doses of the active ingredient paroxetine but the doses can also be the same for both of the active ingredients.
- the present invention provides the use of the composition comprising a first component (a) which is ' ⁇ -3-NN-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-l- benzopyran-5-carboxamide hydrogen (2 ⁇ ,3i?)-tartrate monohydrate and a second component (b) which is paroxetine, in the treatment of 5-hydroxytryptamine mediated disorders, such as affective disorders.
- a which is ' ⁇ -3-NN-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-l- benzopyran-5-carboxamide hydrogen (2 ⁇ ,3i?)-tartrate monohydrate
- a second component (b) which is paroxetine in the treatment of 5-hydroxytryptamine mediated disorders, such as affective disorders.
- affective disorders are disorders in the C ⁇ S such as mood disorders (depression, major depressive episodes, dysthymia, seasonal affective disorder, depressive phases of bipolar disorder), anxiety disorders (obsessive compulsive disorder, panic disorder with/without agoraphobia, social phobia, specific phobia, generalized anxiety disorder, posttraumatic stress disorder), personality disorders (disorders of impulse control, trichotellomania) and sleep disorders.
- disorders in the C ⁇ S such as eating disorders (obesity, anorexia, bulimia), premenstrual syndrome, sexual disturbances, alcoholism, tobacco abuse, autism, attention deficit, hyperactivity disorder, migraine, memory disorders (age associated memory impairment, presenile and senile dementia such as Alzheimer's disease), pathological aggression, schizophrenia, endocrine disorders (e g hyperprolactinaemia), stroke, dyskinesia, Parkinson's disease, thermoregulatory disorders, pain and hypertension may also be treated with the combination described herein.
- hydroxytryptamine mediated disorders are urinary incontinence, vasospasm and growth control of tumors (e g lung carcinoma) and it may be possible to treat those with the combination described herein as well.
- NAD 299 could antagonize the suppression of firing in serotoninerglc dorsal raphe neurones in rats induced by paroxetine (Figure).
- Figure shows medians +semi-interquartile range based on recordings from 5 animals per group.
- the paroxetine- induced suppression was statistically significantly antagonised by NAD 299 treatment (p ⁇ 0.05).
- SSRIs selective serotonin reuptake inhibitors
- paroxetine selective serotonin reuptake inhibitors
- SSRIs selective serotonin reuptake inhibitors
- the 5-hydroxytryptamine (5-HT) transporter protein affected is present both in somatodendritic and terminal regions, and initially the enhanced availability of serotonin in the former areas will inhibit neuronal activity as well as forebrain synthesis and release of 5-HT through activation of inhibitory 5-HTJA autoreceptors.
- these receptors desensitize with time there is a gradual increase in forebrain serotonin release, as has been shown in animals studies, and the time-course for this phenomenon probably explains the delayed onset of antidepressant actions clinically.
- a suitable pharmaceutical composition comprising a first component (a) and a second component (b) in a single dosage form include the following:
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL99346763A PL346763A1 (en) | 1998-09-16 | 1999-09-13 | A new composition |
BR9913748-8A BR9913748A (en) | 1998-09-16 | 1999-09-13 | Composition, use of composition method for the treatment of disorders mediated by 5-ht, method of improving the beginning of therapeutic action, pharmaceutical formulation, process for preparing the composition, and, kit |
JP2000569802A JP2002524508A (en) | 1998-09-16 | 1999-09-13 | New composition |
EP99951319A EP1128825A1 (en) | 1998-09-16 | 1999-09-13 | A new composition |
SK326-2001A SK3262001A3 (en) | 1998-09-16 | 1999-09-13 | A new composition |
EEP200100157A EE200100157A (en) | 1998-09-16 | 1999-09-13 | New composition |
KR1020017003337A KR20010099647A (en) | 1998-09-16 | 1999-09-13 | A New Composition |
IL14151999A IL141519A0 (en) | 1998-09-16 | 1999-09-13 | A new composition of (r) -3-n, n-dicyclobutylamino-8-fluoro-3, 4-dihydro-3h-1-benzopyran-5-carboxamide hydrogen (2r, 3r) - tartrate monohydrate and paroxetine |
CA002342341A CA2342341A1 (en) | 1998-09-16 | 1999-09-13 | A new composition |
AU63780/99A AU6378099A (en) | 1998-09-16 | 1999-09-13 | A new composition |
IS5879A IS5879A (en) | 1998-09-16 | 2001-03-07 | New preparation |
NO20011312A NO20011312L (en) | 1998-09-16 | 2001-03-15 | New composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9803156A SE9803156D0 (en) | 1998-09-16 | 1998-09-16 | A new composition |
SE9803156-0 | 1998-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000015218A1 true WO2000015218A1 (en) | 2000-03-23 |
Family
ID=20412627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1999/001597 WO2000015218A1 (en) | 1998-09-16 | 1999-09-13 | A new composition |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1128825A1 (en) |
JP (1) | JP2002524508A (en) |
KR (1) | KR20010099647A (en) |
CN (1) | CN1317964A (en) |
AR (1) | AR021808A1 (en) |
AU (1) | AU6378099A (en) |
BR (1) | BR9913748A (en) |
CA (1) | CA2342341A1 (en) |
CZ (1) | CZ2001961A3 (en) |
EE (1) | EE200100157A (en) |
HU (1) | HUP0103544A3 (en) |
ID (1) | ID28785A (en) |
IL (1) | IL141519A0 (en) |
IS (1) | IS5879A (en) |
NO (1) | NO20011312L (en) |
PL (1) | PL346763A1 (en) |
SE (1) | SE9803156D0 (en) |
SK (1) | SK3262001A3 (en) |
TR (1) | TR200100779T2 (en) |
WO (1) | WO2000015218A1 (en) |
ZA (1) | ZA200101946B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002030405A2 (en) * | 2000-10-13 | 2002-04-18 | Neurosearch A/S | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
EP1859807A1 (en) * | 2005-03-04 | 2007-11-28 | Tokyo Medical and Dental University | Recurrence preventive therapeutic agent for psychostimulant-induced psychosis and schizophrenia |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033710A1 (en) * | 1995-04-27 | 1996-10-31 | Astra Aktiebolag | A combination of a 5-ht uptake inhibitor with a selective 5-ht1a antagonist |
-
1998
- 1998-09-16 SE SE9803156A patent/SE9803156D0/en unknown
-
1999
- 1999-09-13 ID IDW20010581A patent/ID28785A/en unknown
- 1999-09-13 EE EEP200100157A patent/EE200100157A/en unknown
- 1999-09-13 JP JP2000569802A patent/JP2002524508A/en active Pending
- 1999-09-13 SK SK326-2001A patent/SK3262001A3/en unknown
- 1999-09-13 IL IL14151999A patent/IL141519A0/en unknown
- 1999-09-13 CZ CZ2001961A patent/CZ2001961A3/en unknown
- 1999-09-13 AU AU63780/99A patent/AU6378099A/en not_active Abandoned
- 1999-09-13 EP EP99951319A patent/EP1128825A1/en not_active Withdrawn
- 1999-09-13 CN CN99811010A patent/CN1317964A/en active Pending
- 1999-09-13 KR KR1020017003337A patent/KR20010099647A/en not_active Application Discontinuation
- 1999-09-13 CA CA002342341A patent/CA2342341A1/en not_active Abandoned
- 1999-09-13 HU HU0103544A patent/HUP0103544A3/en unknown
- 1999-09-13 PL PL99346763A patent/PL346763A1/en unknown
- 1999-09-13 BR BR9913748-8A patent/BR9913748A/en not_active Application Discontinuation
- 1999-09-13 WO PCT/SE1999/001597 patent/WO2000015218A1/en not_active Application Discontinuation
- 1999-09-13 TR TR2001/00779T patent/TR200100779T2/en unknown
- 1999-09-15 AR ARP990104626A patent/AR021808A1/en not_active Application Discontinuation
-
2001
- 2001-03-07 IS IS5879A patent/IS5879A/en unknown
- 2001-03-08 ZA ZA200101946A patent/ZA200101946B/en unknown
- 2001-03-15 NO NO20011312A patent/NO20011312L/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033710A1 (en) * | 1995-04-27 | 1996-10-31 | Astra Aktiebolag | A combination of a 5-ht uptake inhibitor with a selective 5-ht1a antagonist |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002030405A2 (en) * | 2000-10-13 | 2002-04-18 | Neurosearch A/S | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
WO2002030405A3 (en) * | 2000-10-13 | 2002-09-06 | Neurosearch As | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
US7307087B2 (en) | 2000-10-13 | 2007-12-11 | Neurosearch A/S | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
EP1859807A1 (en) * | 2005-03-04 | 2007-11-28 | Tokyo Medical and Dental University | Recurrence preventive therapeutic agent for psychostimulant-induced psychosis and schizophrenia |
EP1859807A4 (en) * | 2005-03-04 | 2008-04-23 | Univ Tokyo Medical & Dental | Recurrence preventive therapeutic agent for psychostimulant-induced psychosis and schizophrenia |
Also Published As
Publication number | Publication date |
---|---|
EE200100157A (en) | 2002-08-15 |
CA2342341A1 (en) | 2000-03-23 |
HUP0103544A2 (en) | 2002-05-29 |
PL346763A1 (en) | 2002-02-25 |
SK3262001A3 (en) | 2001-08-06 |
JP2002524508A (en) | 2002-08-06 |
EP1128825A1 (en) | 2001-09-05 |
BR9913748A (en) | 2001-07-10 |
CN1317964A (en) | 2001-10-17 |
AU6378099A (en) | 2000-04-03 |
TR200100779T2 (en) | 2001-10-22 |
IL141519A0 (en) | 2002-03-10 |
NO20011312L (en) | 2001-05-16 |
KR20010099647A (en) | 2001-11-09 |
IS5879A (en) | 2001-03-07 |
ID28785A (en) | 2001-07-05 |
HUP0103544A3 (en) | 2003-12-29 |
AR021808A1 (en) | 2002-08-07 |
NO20011312D0 (en) | 2001-03-15 |
SE9803156D0 (en) | 1998-09-16 |
CZ2001961A3 (en) | 2001-08-15 |
ZA200101946B (en) | 2002-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6169098B1 (en) | Composition and methods employing it for the treatment of 5-HT-mediated disorders | |
US8304431B2 (en) | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | |
US20050203130A1 (en) | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | |
JP4571485B2 (en) | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | |
US6472423B1 (en) | Pharmaceutical composition | |
EP1128825A1 (en) | A new composition | |
AU6378199A (en) | A new composition | |
AU6378299A (en) | A new composition | |
JP4571645B2 (en) | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | |
EP1113792A1 (en) | A new composition | |
MXPA01002370A (en) | A new composition | |
MXPA01002543A (en) | A new composition | |
CA2451798C (en) | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99811010.8 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 1999 63780 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 141519 Country of ref document: IL Ref document number: 63780/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 510188 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2342341 Country of ref document: CA Ref document number: 2342341 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/00231/MU Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/002370 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/01946 Country of ref document: ZA Ref document number: 200101946 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3262001 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 2000 569802 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017003337 Country of ref document: KR Ref document number: PV2001-961 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/00779 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999951319 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-961 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1999951319 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017003337 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2001-961 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999951319 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017003337 Country of ref document: KR |